Lilly shares rise on surprising news from FDA on arthritis drug
The Indianapolis drugmaker said it will not be required to conduct another expensive, time-consuming clinical trial for the potential blockbuster.
Eli Lilly and Co.
Articles
Lilly insulin prices come under microscope
Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog shot up 1,157 percent.
Lilly, other drug giants hunt for patients in India’s remote corners
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
Lilly reports 35 percent profit surge, but says key drug might require new clinical trial
The Indianapolis-based drugmaker warned that a much-anticipated new drug for rheumatoid arthritis might be delayed another 18 months.
Lilly to pay up to $400M to buy rights for early-stage immune drug
The deal is Eli Lilly and Co.’s latest push into a growing disease area for such disorders as arthritis, lupus and multiple sclerosis.
Lilly Endowment giving IU medical school $25M to fund life sciences initiatives
The grant from the Indianapolis-based philanthropic giant is aimed at bolstering Indiana’s stature as a life sciences research hub.
British Supreme Court rules in Eli Lilly’s favor in drug dispute
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
Lilly, Purdue seek medical advancements in new $52M collaboration
Eli Lilly and Co. announced the “strategic research collaboration” Thursday morning, calling it the largest agreement of its kind between Purdue and a single company.
Performance gap widening in some generic drugs, researchers say
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
Lilly, Pfizer get boost for non-opioid pain drug
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
Nevada forces drugmakers to reveal insulin pricing, profits
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
First bellwether trial for ‘low-T’ treatment could have ramifications for Lilly
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Lilly CFO Derica Rice to leave company in December
Rice, 52, who had been the company's top finance officer since 2006, is one of the most powerful black executives in corporate America. He had been widely considered a leading candidate to succeed CEO John Lechleiter, but that position went to fellow Lilly executive Dave Ricks.
Lilly hires ‘powerhouse’ D.C. lobbyist
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly migraine drug provides relief in late-stage trials
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
Drug lobby mulling membership reductions amid price scrutiny
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
Lilly executive Pescovitz leaving to become university president
Oakland University in suburban Detroit on Thursday announced that its board of trustees unanimously chose Ora Hirsch Pescovitz for the job after a search involving more than 60 candidates.
Despite setbacks, top Lilly researcher bullish on pipeline’s momentum
The Indianapolis drugmaker is trying to reassure Wall Street that its pipeline is still poised to deliver.
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Lilly profit climbs 18 percent after one-time expenses
The Indianapolis-based drugmaker beat Wall Street expectations by 2 cents a share—performance it attributed to brisk sales of new products.